583829-90-7

Upstream product

• 212970-72-4 {3-[(2,2-dimethyl-1,1-diphenyl-1-silapropoxy)methyl]-(1S,3R,4S,5R)-7,7-dimethyl-2,6,8-trioxa-4-(phenylmethoxy)bicyclo[3.3.0]oct-3-yl}methan-1-ol 
• 26661-13-2 4-N-benzoylcytosine 
• 583829-87-2 4'-C-acetoxymethyl-2'-O-acetyl-4-N-benzoyl-3'-O-benzyl-5'-O-tert-butyldiphenylsilyl-cytidine 
• 583829-88-3 4-N-benzoyl-3'-O-benzyl-5'-O-tert-butyldiphenylsilyl-4'-C-hydroxymethyl-cytidine 
• 583829-86-1 4-C-acetoxymethyl-1,2-di-O-acetyl-3-O-benzyl-5-O-tert-butyldiphenylsilyl-D-erythro-pentofuranose 

Downstream Products

• 877823-46-6 4-N-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O,4'-C-(methylenoxymethylene)cytidine 

Relevant academic research and scientific papers

Synthesis and properties of 2′-O,4′-C-methyleneoxymethylene bridged nucleic acid

A novel bridged nucleic acid (BNA) analogue, 2′-O,4′-C- methyleneoxymethylene bridged nucleic acid (2′,4′-BNA COC), was synthesized and incorporated into oligonucleotides. The 2′,4′-BNACOC modified oligonucleotides showed high bindin

NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDE DERIVATIVE COMPRISING NUCLEOTIDE ANALOGUE THEREOF

Compounds of the following general formula (1) and salts thereof: where A represents a direct bond, an alkylene group having 1 to 4 carbon atoms, etc.; B represents an aromatic heterocyclic group which may have a substituent, etc.; R1, R2